Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Thomas Kirwin who wrote (346)	8/12/1999 7:34:00 AM
From: Thomas Kirwin	Respond to of 422

Register & Akers Fast Fact #9 – Acquisitions, etc “In FY1999, they purchased two of their competitors, Gamma Biologicals and the BCA division of BioPool. Gamma brings to Immucor approximately $18 million in sales, manufacturing facility, and a new microbead reagent technology called ReACT, which is competitive to DiaMed's gel technology and can be automated. It also removed a major price competitor, which should allow firmer pricing going forward. BioPool added $5 million in sales, over 60% of which are generated in North America. It was immediately accretive. The company also executed agreements with European and Japanese distributors, and continued development of new generation instrumentation as well as upgrades and add-ons which enhance efficiency and reduce errors. The resultant financial and operating profile of Immucor has changed meaningfully, vaulting the company into solid third place in its industry, and closing on its competitors.” Best O'Luck! Tom

To: Thomas Kirwin who wrote (346)	8/12/1999 7:35:00 AM
From: Thomas Kirwin	Respond to of 422

Register & Akers Fast Fact #10 - Sales/Earnings Forecast "Our forecast for future sales and earnings is, in our opinion, not only reasonable, but beatable - especially if Immucor lands a few major accounts. We also believe our margin assumptions could prove to be conservative, as gross margins on instrument reagent sales are significantly higher than our 54% to 55% assumptions. We are looking for FY1999 results of $59.3 million in sales and EPS of $0.42. Based on instrument assumptions, we look for a 52% gain in FY2000 revenue to $90 million, with gross and operating margin improvement producing a 79% gain in net income. Per share earnings will be restricted to a 67% gain, due to more shares from the exercise of options in calculating results. We look for similar influences to impact FY2001 results, with manual reagent sales beginning to be cannibalized by higher-margined reagents sold in conjunction with instruments. We are conservatively projecting a 25% increase in revenue to $113 million producing an 81% increase in net income to $10.8 million or $1.10 per share. We would not be surprised to be low."